Pacira Pharmaceuticals Inc (PCRX)

Quick ratio

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash US$ in thousands 153,298 104,139 585,578 99,957 78,228
Short-term investments US$ in thousands 125,283 184,512 70,831 421,705 213,722
Receivables US$ in thousands 105,556 98,397 96,318 53,046 47,530
Total current liabilities US$ in thousands 97,383 147,774 521,118 253,328 107,673
Quick ratio 3.94 2.62 1.44 2.27 3.15

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($153,298K + $125,283K + $105,556K) ÷ $97,383K
= 3.94

The quick ratio, also known as the acid-test ratio, measures a company's ability to cover its short-term liabilities with its most liquid assets. A higher quick ratio indicates a stronger liquidity position and suggests that the company can easily meet its short-term obligations.

For Pacira BioSciences Inc, the quick ratio has fluctuated over the past five years, as follows:

- Dec 31, 2023: 4.17
- Dec 31, 2022: 2.72
- Dec 31, 2021: 1.47
- Dec 31, 2020: 2.32
- Dec 31, 2019: 3.25

The trend indicates an improving liquidity position from 2019 to 2023, with the quick ratio consistently above 1, indicating that Pacira BioSciences Inc can cover its short-term liabilities with its quick assets. The quick ratio peaked at 4.17 in 2023, reflecting a substantial increase in liquidity compared to previous years.

Overall, the increasing trend in Pacira BioSciences Inc's quick ratio signifies a strengthening liquidity position, which suggests the company's ability to meet its short-term obligations and indicates financial stability.


Peer comparison

Dec 31, 2023